Maintenance Notice (4:30 AM - 11:00 AM December 21, 2024): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 231277-92-2 | Product Number: L0360
Lapatinib
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 250MG |
€96.00
|
1 | 5 |
|
| 1G |
€247.00
|
1 | ≥40 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | L0360 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__9H__2__6ClFN__4O__4S = 581.06 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image), 250MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 231277-92-2 |
| Reaxys Registry Number | 10502247 |
| PubChem Substance ID | 468592164 |
| MDL Number | MFCD09264194 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 145.0 to 149.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 147 °C |
| Maximum Absorption Wavelength | 367(MeOH) nm |
GHS
| Hazard Statements | H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
Related Laws:
| RTECS# | VA0952500 |
Transport Information:
| HS Number | 2934999090 |
Application
Lapatinib: A Dual Kinase Inhibitor of EGFR and HER2
Lapatinib (GW572016) is a 4-anilinoquinazoline dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. Advanced breast cancer or metastatic breast cancer often overexpress HER2 which is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Lapatinib plus capecitabine [C2878] (a prodrug of 5-FU [F0151]) has shown potent activity in solid tumors, with the most notable in advanced or metastatic breast cancer. (The product is for research purpose only.)
References
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases (a review)
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.